XOMA Royalty Corporation (XOMA)
NASDAQ: XOMA · Real-Time Price · USD
41.97
+0.17 (0.41%)
At close: May 14, 2026, 4:00 PM EDT
42.00
+0.03 (0.07%)
After-hours: May 14, 2026, 4:10 PM EDT
XOMA Royalty Revenue
XOMA Royalty had revenue of $12.32M in the quarter ending March 31, 2026, a decrease of -22.59%. This brings the company's revenue in the last twelve months to $48.56M, up 13.16% year-over-year. In the year 2025, XOMA Royalty had annual revenue of $52.15M with 83.06% growth.
Revenue (ttm)
$48.56M
Revenue Growth
+13.16%
P/S Ratio
10.81
Revenue / Employee
$3,468,214
Employees
14
Market Cap
526.35M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 52.15M | 23.66M | 83.06% |
| Dec 31, 2024 | 28.49M | 23.73M | 498.72% |
| Dec 31, 2023 | 4.76M | -1.27M | -21.06% |
| Dec 31, 2022 | 6.03M | -32.13M | -84.21% |
| Dec 31, 2021 | 38.16M | 8.78M | 29.86% |
| Dec 31, 2020 | 29.39M | 11.02M | 59.96% |
| Dec 31, 2019 | 18.37M | 13.07M | 246.67% |
| Dec 31, 2018 | 5.30M | -47.39M | -89.94% |
| Dec 31, 2017 | 52.69M | 47.13M | 846.98% |
| Dec 31, 2016 | 5.56M | -49.88M | -89.97% |
| Dec 31, 2015 | 55.45M | 36.58M | 193.90% |
| Dec 31, 2014 | 18.87M | -16.59M | -46.78% |
| Dec 31, 2013 | 35.45M | 1.67M | 4.94% |
| Dec 31, 2012 | 33.78M | -24.41M | -41.95% |
| Dec 31, 2011 | 58.20M | 24.56M | 72.99% |
| Dec 31, 2010 | 33.64M | -64.79M | -65.82% |
| Dec 31, 2009 | 98.43M | 30.44M | 44.78% |
| Dec 31, 2008 | 67.99M | -16.27M | -19.31% |
| Dec 31, 2007 | 84.25M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rigel Pharmaceuticals | 299.77M |
| REGENXBIO | 170.44M |
| Assembly Biosciences | 71.10M |
| Prothena Corporation | 57.94M |
| Ovid Therapeutics | 7.25M |
| Ocugen | 4.47M |
| Upstream Bio | 2.85M |
| Shattuck Labs | 1.00M |
XOMA News
- 14 days ago - Xoma downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 17 days ago - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation - PRNewsWire
- 17 days ago - Ligand price target raised to $255 from $230 at Stifel - TheFly
- 17 days ago - Xoma downgraded to Neutral from Buy at Lucid Capital - TheFly
- 17 days ago - Ligand to acquire Xoma for $39.00 per share in cash - TheFly
- 17 days ago - Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator - GlobeNewsWire
- 17 days ago - Ligand to buy Xoma for $39 per share, WSJ reports - TheFly
- 2 months ago - XOMA Royalty Declares Quarterly Preferred Stock Dividends - GlobeNewsWire